Teachers Retirement System of The State of Kentucky Boosts Stock Position in Insulet Co. (NASDAQ:PODD)

Teachers Retirement System of The State of Kentucky lifted its holdings in Insulet Co. (NASDAQ:PODD) by 23.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 35,035 shares of the medical instruments supplier’s stock after purchasing an additional 6,754 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.05% of Insulet worth $6,006,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Consolidated Portfolio Review Corp boosted its stake in Insulet by 1.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock worth $806,000 after buying an additional 57 shares during the period. FourThought Financial Partners LLC lifted its position in shares of Insulet by 1.4% during the fourth quarter. FourThought Financial Partners LLC now owns 4,461 shares of the medical instruments supplier’s stock worth $968,000 after purchasing an additional 61 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its position in shares of Insulet by 1.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock worth $1,262,000 after purchasing an additional 73 shares during the last quarter. Lindbrook Capital LLC lifted its position in shares of Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the last quarter. Finally, Moody National Bank Trust Division lifted its position in shares of Insulet by 2.6% during the first quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock worth $589,000 after purchasing an additional 87 shares during the last quarter.

Analyst Upgrades and Downgrades

PODD has been the subject of several recent research reports. Jefferies Financial Group lifted their price objective on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. OTR Global restated a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Canaccord Genuity Group restated a “buy” rating and issued a $234.00 price objective on shares of Insulet in a report on Tuesday, July 23rd. Barclays decreased their price objective on Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Finally, Redburn Atlantic began coverage on Insulet in a report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average target price of $239.18.

Insider Activity

In other news, SVP Mark N. Field sold 1,500 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the completion of the sale, the senior vice president now owns 12,875 shares in the company, valued at $2,574,485. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Insulet news, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the sale, the senior vice president now owns 12,875 shares in the company, valued at approximately $2,574,485. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Timothy J. Scannell sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.51, for a total value of $1,333,570.00. Following the sale, the director now owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,931 shares of company stock worth $2,636,286. 0.47% of the stock is currently owned by corporate insiders.

Insulet Trading Down 0.4 %

NASDAQ PODD traded down $0.80 during trading hours on Friday, hitting $196.45. 843,823 shares of the company’s stock were exchanged, compared to its average volume of 622,718. The business’s 50 day moving average is $194.74 and its 200-day moving average is $184.32. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $269.33. The firm has a market capitalization of $13.76 billion, a P/E ratio of 59.53, a price-to-earnings-growth ratio of 3.55 and a beta of 1.16. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, topping the consensus estimate of $0.39 by $0.34. The company had revenue of $441.70 million during the quarter, compared to analyst estimates of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The firm’s revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.23 earnings per share. As a group, analysts anticipate that Insulet Co. will post 3.11 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.